Although tuberculosis is a major cause of morbidity and
mortality worldwide, available funding falls far short of that required
for effective control. Economic and spillover consequences of investments
in the treatment of tuberculosis are unclear, particularly when
steep gradients in the disease and response are linked by population
movements, such as that between Papua New Guinea (PNG) and the
Australian cross-border region.